申请人:Pfizer Limited
公开号:EP0148623A2
公开(公告)日:1985-07-17
A quinolone inotropic agent of the formula:
or a pharmaceutically acceptable salt thereof, wherein «Het» is an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group attached by a carbon atom to the 5-, 6-, 7- or 8- position of said quinolone; R, which is attached to the 5-, 6-, 7- or 8- position, is hydrogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulphinyl, C1-C4 alkylsulphonyl, halo, CF3, hydroxy, hydroxymethyl, or cyano; R1 is hydrogen, cyano (C1-C4 alkoxy)carbonyl, C1-C4 alkyl, nitro, halo, -NR3R4 or -CONR3R4 where R3 and R4 are each independently H or C1-C4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic group optionally containing a further heteroatom or group selected from 0, S and N-R5 where R5 is H or C1-C4 alkyl; R2 is H, C1-C4 alkyl, or 2-hydroxyethyl; Y is H or C1-C4 alkyl; and the dotted line between the 3- and 4- positions represents an optional bond.
式中的喹诺酮类肌力剂:
或其药学上可接受的盐,其中 "Het "是通过一个碳原子连接到所述喹诺酮的5、6、7或8-位的任选取代的5或6元单环芳香杂环基团;连接到5、6、7或8-位的R是氢、C1-C4烷基、C1-C4烷氧基、C1-C4烷硫基、C1-C4烷基亚磺酰基、C1-C4烷基磺酰基、卤素、CF3、羟基、羟甲基或氰基;R1 是氢、氰基(C1-C4 烷氧基)羰基、C1-C4 烷基、硝基、卤素、-NR3R4 或-CONR3R4,其中 R3 和 R4 各自独立地是 H 或 C1-C4 烷基,或与它们所连接的氮原子一起形成饱和的 5 或 6 元杂环基团,该杂环基团可选择含有另一个杂原子或选自 0、S 和 N-R5 的基团,其中 R5 是 H 或 C1-C4 烷基;R2 是 H、C1-C4 烷基或 2-羟乙基;Y 是 H 或 C1-C4 烷基;3- 和 4-位置之间的虚线代表任选键。